Glioblastoma multiforme, a high-grade glioma, is the most prevalent and aggressive malignant
tumor of the central nervous system. Glioblastoma multiforme is the leading cause of death by
disease in children. With the currently available treatment, the median overall survival of
glioblastoma patients is 13.9 months with 2-year survival of 22.5% and 5-year survival of 5.3%.
Compounding the poor patient survival rates, currently available treatments often cause
debilitating side-effects, resulting in poor quality of life. This poor patient survival rate and
horrendous end-of-life quality highlights an urgent need to identify novel strategies to target
glioblastoma multiforme. As recent reports and key opinion leaders suggest, glioblastoma multiforme is a
disorder with one of the highest unmet needs in oncology. In partnership with world class
eurosurgeons and medicinal chemists we aim to develop pharmaceuticals that
we have discovered to treat glioblastoma multiforme patients. Hemispherian
scientists have identified and are advancing two compounds that are highly effective in
treating these deadly brain tumors.